To evaluate whether the therapeutic enhancement seen with NDV-ICOSL virus was mediated through the ICOS pathway, the combination of NDV-ICOSL/anti-CTLA-4 was also evaluated in ICOS−/− mice using a larger tumour challenge (Supplementary Fig. 7c,d). This evidence concerns the gene CTLA4 and neoplasm.